Alpha/beta-polypeptide analogs of glucagon-like peptide-1
Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one α-amino acid found in the native GLP-1 is replaced with a β-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
1. A composition of matter comprising an isolated, unnatural analog of glucagon-like peptide 1 (GLP-1) having an N-terminus, wherein at least one α-amino acid residue in the GLP-1 located at least 12 residues from the N-terminus of the GLP-1 is replaced with a β-amino acid residue, wherein when more than one (1) β-amino acid residue is present in the GLP-1 analog, the β-amino acid residues appear in the pattern -αααβ-αααβ-.
2. A synthetic, unnatural polypeptide having an amino acid sequence of
H-H-X-EGTFT-X-D-X-S-X-YLE-X-QAA-X-EFI-X-WLV-X-GRG-NH 2 (SEQ. ID. NO: 16), wherein X at position 2 is Ala or 2-aminoisobutyric acid (“Aib”); X at position 8 is Ser or 2-aminocyclopentane carboxylic acid (“ACPC”); X at position 10 is Val or Aib; X at position 12 is Ser, β 3 -Ser, Aib or ACPC; X at position 16 is Gly, β 3 -Gly, Aib, or ACPC; X at position 20 is β 3 -Lys, Aib, or ACPC; X at position 24 is Ala, Aib, or ACPC; and X at position 28 is Lys, β 3 -Lys, Aib or 3-aminopyrrolidine-4-carboxylic acid.
3. A synthetic, unnatural polypeptide selected from the group consisting of SEQ. ID. NOS: 2-7 and 11-13.
4. A method to stimulate a glucagon-like peptide-1 receptor in vitro, the method comprising contacting the receptor with a composition of matter as recited in claim 1 .
5. A method to stimulate a glucagon-like peptide-1 receptor in vivo in a mammalian subject, the method comprising administering to the subject a glucagon-like peptide-1 receptor agonist-effective amount of a composition of matter as recited in claim 1 .
6. A pharmaceutical composition comprising a composition of matter as recited in claim 1 , in combination with a pharmaceutically suitable carrier.
7. A method to treat hyperglycemia in a mammalian subject, the method comprising administering to the subject an anti-hyperglycemic-effective amount of a composition of matter as recited in claim 1 .
8. A method to treat diabetes in a mammalian subject, including a human subject, the method comprising administering to the subject an anti-diabetic-effective amount of a composition of matter as recited in claim 1 .
9. The method of claim 5 , where the mammalian subject is a human subject.
10. The method of claim 7 , where the mammalian subject is a human subject.
11. The method of claim 8 , where the mammalian subject is a human subject.